ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zimmer Biomet is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some supportive elements, including a sizable new buyback plan and positive option sentiment, but the broader setup is mixed: analysts have recently lowered targets, most ratings are Neutral/Hold, and the technical trend is still not fully constructive. Since the user is impatient and wants a direct answer, my view is to wait rather than buy aggressively now.
ZBH is showing short-term improvement, but the overall trend is still not a clean uptrend. MACD histogram is positive and expanding, which is a bullish momentum sign. RSI_6 at 51.9 is neutral, so the stock is not overbought or oversold. However, the moving average structure remains bearish with SMA_200 > SMA_20 > SMA_5, which suggests the longer-term trend has not fully turned higher yet. Price at 83.61 is just above pivot 82.315 and near R1 84.637, so upside from here looks limited unless it breaks resistance. The pattern-based outlook also points to possible near-term softness before modest medium-term recovery.
["Zimmer Biomet announced up to $1 billion in share repurchases for fiscal 2026.", "The buyback sits under the existing $1.5 billion authorization, showing management support for the stock.", "Q1 results included a revenue beat and stronger EPS, with margins helped by tariff-related benefits.", "The company maintained revenue guidance and raised EPS guidance.", "MACD momentum is improving, suggesting near-term price stabilization.", "Options open interest leans mildly bullish with a put-call ratio below 1."]
["Several analysts lowered price targets after Q1, showing reduced expectations.", "Most recent ratings are Hold or Neutral, with only a few bullish calls.", "Buy-side expectations were higher than the 2.9% organic revenue growth delivered in Q1.", "Core performance was described as mixed and 2026 is still viewed as a transitional year.", "Technical trend remains bearish on moving averages.", "Options volume is heavily put-skewed, suggesting hedging or short-term caution.", "No significant insider buying, hedge fund accumulation, or congress trading support has been reported."]
The latest quarter was Q1 2026. Zimmer Biomet posted a modest earnings beat and 2.9% organic revenue growth, but that growth was below stronger buy-side expectations. Management kept revenue guidance unchanged and raised EPS guidance, helped by tariff-related margin benefits. Overall, the quarter was solid but not high-growth, and the business still appears to be in a transition phase rather than a strong acceleration phase.
Recent analyst sentiment has turned more cautious. Truist, JPMorgan, Citi, Baird, and Barclays all lowered price targets after Q1, with several maintaining Hold/Neutral/Underweight-type views. Stifel, Citizens, and Canaccord still have bullish ratings, but the tone is mixed and the consensus is more defensive than optimistic. Wall Street pros see some value and buyback support, but they also see limited near-term upside, moderate growth, and a 2026 transition period as meaningful drawbacks.
